Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 4/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.51 |
| ▸ | CYP2E1 | P05181 | 3/20 | 0.51 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.51 |
| ▸ | CYP2B6 | P20813 | 3/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | AOC1 | P19801 | 7/20 | 0.48 |
| ▸ | AOC3 | Q16853 | 7/20 | 0.48 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | MGAT2 | Q10469 | 1/20 | 0.42 |
| ▸ | MELK | Q14680 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31119316 | 1.00 | CYP1A2 (0.51) | CYP1A2CYP2C19CYP2E1CYP2A6CYP2B6 | |
| SCHEMBL34462738 | 0.85 | TAAR1 (0.56) | CYP1A2CYP2C19CYP2E1CYP2A6CYP2B6 | |
| SCHEMBL4893069 | 0.84 | AOC1 (0.53) | CYP1A2CYP2C19CYP2E1CYP2A6CYP2B6 | |
| Hydrochloric Acid SCHEMBL18986455 | 0.82 | AOC1 (0.55) | CYP1A2CYP2C19CYP2E1CYP2A6CYP2B6 | |
| SCHEMBL12097845 | 0.82 | CYP1A2 (0.46) | CYP1A2CYP2C19CYP2E1CYP2A6CYP2B6 | |
| SCHEMBL91395 | 0.82 | CA12 (0.50) | CYP1A2CYP2C19CYP2E1CYP2A6CYP2B6 | |
| SCHEMBL1847294 | 0.80 | SLC6A4 (0.46) | CYP1A2CYP2C19CYP2E1CYP2A6CYP2B6 | |
| SCHEMBL21847315 | 0.80 | SLC6A2 (0.46) | CYP1A2CYP2C19CYP2E1CYP2A6CYP2B6 | |
| SCHEMBL1770449 | 0.80 | CYP11B1 (0.45) | CYP1A2CYP2C19CYP2E1CYP2A6CYP2B6 | |
| SCHEMBL5179904 | 0.80 | SLC6A2 (0.46) | CYP1A2CYP2C19CYP2E1CYP2A6CYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4034257-B1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2024-05-22 | — | — | EP | disclosed |
| US-11952344-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-04-09 | — | — | US | disclosed |
| US-20220340527-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-10-27 | — | — | US | disclosed |
| EP-4034257-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2022-08-03 | — | — | EP | disclosed |
| US-20220048889-A1 | HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-02-17 | — | — | US | disclosed |
| EP-3723807-B1 | COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF 1H-PYRAZOLO[4,3-B]PYRIDINES | H LUNDBECK AS (DK) | 2021-10-20 | — | — | EP | disclosed |
| EP-3723808-B1 | COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF 1H-PYRAZOLO[4,3-B]PYRIDINES | H LUNDBECK AS (DK) | 2021-10-20 | — | — | EP | disclosed |
| US-11026923-B2 | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors | H. LUNDBECK A/S (DK) | 2021-06-08 | — | — | US | disclosed |
| US-11026924-B2 | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors | H. LUNDBECK A/S (DK) | 2021-06-08 | — | — | US | disclosed |
| WO-2021059017-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-04-01 | — | — | WO | disclosed |
| WO-2010024430-A1 | 2,4-DIAMINOPYRIMIDINE COMPOUND | アステラス製薬株式会社 (JP) | 2010-03-04 | — | — | WO | disclosed |
| US-7601714-B2 | Pyrimidine derivatives useful as inhibitors of PKC-theta | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-7601714-B2 | Pyrimidine derivatives useful as inhibitors of PKC-theta | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-7601714-B2 | Pyrimidine derivatives useful as inhibitors of PKC-theta | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-20080287410-A1 | PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA | BARBOSA ANTONIO J M | 2008-11-20 | — | — | US | disclosed |
| US-20080287410-A1 | PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA | BARBOSA ANTONIO J M | 2008-11-20 | — | — | US | disclosed |
| US-20080287410-A1 | PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA | BARBOSA ANTONIO J M | 2008-11-20 | — | — | US | disclosed |
| EP-1765791-A1 | PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006014482-A1 | PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-02-09 | — | — | WO | disclosed |
| US-20060025433-A1 | Pyrimidine derivatives useful as inhibitors of PKC-theta | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287410-A1 | PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA | PRKCZ, PRKCQ, PRKCH | CYP1A2 2028/4885CYP2C19 1529/4885CYP2E1 1727/4885 |
| US-11026924-B2 | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors | PDE3A, PDE5A, PDE12 | CYP1A2 157/4885CYP2C19 193/4885CYP2E1 423/4885 |
| US-20220340527-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | GRIN1, GRIN2A, GRIN2B | CYP1A2 3901/4885CYP2C19 3809/4885CYP2E1 4570/4885 |
| US-11026923-B2 | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors | PDE3A, PDE5A, PDE12 | CYP1A2 170/4885CYP2C19 207/4885CYP2E1 470/4885 |
| US-20060025433-A1 | Pyrimidine derivatives useful as inhibitors of PKC-theta | PRKCZ, PRKCQ, PRKCH | CYP1A2 2028/4885CYP2C19 1529/4885CYP2E1 1727/4885 |
| US-20220048889-A1 | HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS | VHL, FANCI, PAH | CYP1A2 33/4885CYP2C19 19/4885CYP2E1 16/4885 |
| US-11952344-B2 | Heterocyclic compound and use thereof | GRIN1, GRIN2A, GRIN2B | CYP1A2 3901/4885CYP2C19 3809/4885CYP2E1 4570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.